200 related articles for article (PubMed ID: 26099982)
1. Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.
Errico A
Nat Rev Clin Oncol; 2015 Aug; 12(8):435. PubMed ID: 26099982
[No Abstract] [Full Text] [Related]
2. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Valsecchi ME
N Engl J Med; 2015 Sep; 373(13):1270. PubMed ID: 26398077
[No Abstract] [Full Text] [Related]
3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Larkin J; Hodi FS; Wolchok JD
N Engl J Med; 2015 Sep; 373(13):1270-1. PubMed ID: 26398076
[No Abstract] [Full Text] [Related]
4. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
5. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
[TBL] [Abstract][Full Text] [Related]
7. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
9. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
10. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies and accepted therapies of advanced melanoma].
Liszkay G
Magy Onkol; 2016 Mar; 60(1):11-5. PubMed ID: 26934345
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab + ipilimumab ups melanoma response.
Cancer Discov; 2015 Jun; 5(6):OF2. PubMed ID: 25898833
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab-Based
Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events With Ipilimumab Monotherapy and Combination Therapy With Nivolumab.
Madden KM; Hoffner B
Clin J Oncol Nurs; 2017 Aug; 21(4 Suppl):30-41. PubMed ID: 28738054
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab and Nivolumab for Treatment of Eyelid Spindle Cell Melanoma.
Shoji MK; Rong AJ
Am J Ophthalmol; 2023 Jun; 250():e1-e2. PubMed ID: 36801380
[No Abstract] [Full Text] [Related]
16. Combined immunotherapy improves survival in metastatic melanoma.
Mayor S
BMJ; 2015 Jun; 350():h2993. PubMed ID: 26036979
[No Abstract] [Full Text] [Related]
17. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.
Heppt MV; Schlaak M; Eigentler TK; Kähler KC; Kiecker F; Loquai C; Meier F; Tomsitz D; Brenner N; Niesert AC; Thonke R; Hauschild A; Berking C
Ann Oncol; 2017 Dec; 28(12):3104-3106. PubMed ID: 28950303
[No Abstract] [Full Text] [Related]
18. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
19. Ipilimumab with fotemustine in metastatic melanoma.
Garbe C
Lancet Oncol; 2012 Sep; 13(9):851-2. PubMed ID: 22894885
[No Abstract] [Full Text] [Related]
20. Nivolumab and relatlimab as frontline therapy in advanced melanoma.
Khushalani NI
Clin Adv Hematol Oncol; 2022 Oct; 20(10):602-605. PubMed ID: 36206071
[No Abstract] [Full Text] [Related]
[Next] [New Search]
